OptiNose Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>OP</div>
OPTN -- USA Stock  

USD 4.09  0.03  0.74%

This short post will outline OptiNose as a possible investment alternative for your portfolios. We will provide a perspective on OptiNose future direction.
Published over three weeks ago
View all stories for OptiNose | View All Stories
Are OptiNose (NASDAQ:OPTN) institutional investors starting to hold back?
This firm has a beta of 0.5468. Let's try to break down what OptiNose's beta means in this case. OptiNose returns are very sensitive to returns on the market. As the market goes up or down, OptiNose is expected to follow. The beta indicator helps investors understand whether OptiNose moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if OptiNose deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as OptiNose. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for OptiNose

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of OptiNose's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of OptiNose in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as OptiNose. Your research has to be compared to or analyzed against OptiNose's peers to derive any actionable benefits. When done correctly, OptiNose's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in OptiNose.

How important is OptiNose's Liquidity

OptiNose financial leverage refers to using borrowed capital as a funding source to finance OptiNose ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. OptiNose financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between OptiNose's total debt and its cash.

How OptiNose utilizes its cash?

To perform a cash flow analysis of OptiNose, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash OptiNose is receiving and how much cash it distributes out in a given period. The OptiNose cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Exercise or conversion by Ramy Mahmoud of 28341 shares of OptiNose subject to Rule 16b-3

Legal trades by OptiNose insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
OptiNose insider trading alert for exercise of stock option (right to buy) by Ramy Mahmoud, President and COO, on 29th of December 2020. This event was filed by Optinose Inc with SEC on 2020-12-29. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

OptiNose shows above-average downside volatility for the selected time horizon. We advise investors to inspect OptiNose further and ensure that all market timing and asset allocation strategies are consistent with the estimation of OptiNose future alpha.

Are you still uncommitted about OptiNose?

OptiNose latest skewness surges over 0.66. OptiNose shows above-average downside volatility for the selected time horizon. We advise investors to inspect OptiNose further and ensure that all market timing and asset allocation strategies are consistent with the estimation of OptiNose future alpha.

The Current Takeaway on OptiNose Investment

Whereas few other entities in the drug manufacturers?specialty & generic industry are either recovering or due for a correction, OptiNose may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current OptiNose valuation and our trade advice on OptiNose is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to OptiNose.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of OptiNose. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com